Lexicon Pharmaceuticals Inc logo

Lexicon Pharmaceuticals Inc(LXRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.79
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LXRX

11/13/2026: LXRX (1-star) is currently NOT-A-BUY. Pass it for now.

Lexicon Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering and developing precision small-molecule medicines for chronic conditions like heart failure and neuropathic pain. The company's primary strengths include its approved cardiovascular drug INPEFA and a promising clinical pipeline addressing high unmet medical needs. Its main investment appeal lies in potential label expansions and lucrative partnership milestones, balanced against risks such as modest initial commercial sales, high cash burn, and intense market competition. The stock suits risk-tolerant growth investors willing to monitor clinical readouts and regulatory catalysts closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile pipeline expansion offers high potential growth, current revenue scale remains relatively small.
Momentum investorStrong fit while signal remains positiveStock price responds sharply to binary clinical readouts and regulatory announcements.
Value investorWeak fitThe company is not currently profitable and lacks traditional earnings-based valuation support.
Dividend investorWeak fitLexicon does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical, regulatory, and price volatility risks make it unsuitable for conservative profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks experience sharp price swings around clinical data releases and regulatory updates.
Valuation riskMedium / highValuation is largely speculative based on future pipeline potential rather than current earnings.
Competition risk (cardiovascular & pain therapeutics)HighWell-capitalized pharmaceutical giants dominate the core therapeutic markets.
Business qualityMediumThe company features innovative science but lacks consistent profitability or massive commercial scale.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccessful clinical trial execution and commercial adoption are vital for survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 796.97M USD
Price to earnings Ratio -
1Y Target Price 4.51
Price to earnings Ratio -
1Y Target Price 4.51
Volume (30-day avg) 2.1M shares
Beta 1.08
52 Weeks Range 1.10 - 2.68
Updated Date 11/15/2026
52 Weeks Range 1.10 - 2.68
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.15

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -30.8%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LXRX receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
LXRX has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+74.9%) and strong revenue growth (+60.2%) are partially offset by weak cash generation (FCF margin -136.2%), weak profitability (net margin -101.1%), modest insider ownership of 1.53%.

Financial Health Rating

★★★★★
LXRX's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 43.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is LXRX's strongest growth driver at +74.9% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+60.2%, strong) and free-cash-flow growth (+62.3%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 87.3% and approximately 49.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.53% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Artal Group S A 39.36%
FMR Inc 11.64%
Siren, L.L.C. 9.96%
Sessa Capital, L.P 4.26%
BlackRock Inc 3.90%

Unit Economics (Per $1K Revenue)

★★★★★
LXRX generates approximately $994 of gross profit, $-982 of operating income, and $-1,362 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
LXRX has a Short Squeeze Candidate profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesNet sales generated in the United States from INPEFA (sotagliflozin) for cardiovascular indications.Direct product sales are currently modest and represent an early-stage revenue stream.
Licensing and CollaborationUpfront payments, development milestones, and collaboration revenues from global partners like Viatris and Novo Nordisk.Partnership deals provide crucial non-dilutive capital injections to support research efforts.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 667.30M
Price to Sales(TTM) 20.68
Enterprise Value 667.30M
Price to Sales(TTM) 20.68
Enterprise Value to Revenue 17.32
Enterprise Value to EBITDA 16.57
Shares Outstanding 445.23M
Shares Floating 219.23M
Shares Outstanding 445.23M
Shares Floating 219.23M
Percent Insiders 1.53
Percent Institutions 87.29

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.